199 related articles for article (PubMed ID: 24178790)
1. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia.
Vellanki P; Lange K; Elaraj D; Kopp PA; El Muayed M
J Clin Endocrinol Metab; 2014 Feb; 99(2):387-90. PubMed ID: 24178790
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
3. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB
Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399
[TBL] [Abstract][Full Text] [Related]
4. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.
Tong CV; Hussein Z; Noor NM; Mohamad M; Ng WF
QJM; 2015 Jan; 108(1):49-50. PubMed ID: 25099611
[No Abstract] [Full Text] [Related]
5. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
[TBL] [Abstract][Full Text] [Related]
6. Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report.
Roukain A; Alwan H; Bongiovanni M; Sykiotis GP; Kopp PA
Front Endocrinol (Lausanne); 2021; 12():794988. PubMed ID: 35173680
[TBL] [Abstract][Full Text] [Related]
7. Resistant hypercalcaemia in metastatic parathyroid carcinoma.
Bowyer SE; White AM; Ransom DT; Davidson JA
Med J Aust; 2013 Jun; 198(10):559-61. PubMed ID: 23725272
[No Abstract] [Full Text] [Related]
8. Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma.
Makino H; Notsu M; Asayama I; Otani H; Morita M; Yamamoto M; Yamauchi M; Nakao M; Miyake H; Araki A; Uchino S; Kanasaki K
Intern Med; 2022 Nov; 61(22):3383-3390. PubMed ID: 35370235
[TBL] [Abstract][Full Text] [Related]
9. Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment.
Tzotzas T; Goropoulos A; Karras S; Terzaki A; Siolos A; Doumas A; Zaramboukas T; Tigas S
Hormones (Athens); 2022 Mar; 21(1):171-176. PubMed ID: 34993886
[TBL] [Abstract][Full Text] [Related]
10. Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy.
Jumpertz von Schwartzenberg R; Elbelt U; Ventz M; Mai K; Kienitz T; Maurer L; Rose T; Rückert JC; Strasburger CJ; Spranger J
Endocrinol Diabetes Metab Case Rep; 2015; 2015():150082. PubMed ID: 26605043
[TBL] [Abstract][Full Text] [Related]
11. Is denosumab a long-term option for the treatment of parathyroid carcinoma?
Baretić M
QJM; 2016 Apr; 109(4):288. PubMed ID: 26803154
[No Abstract] [Full Text] [Related]
12. Response to "Is denosumab a long-term option for the treatment of parathyroid carcinoma?".
Tong CV; Hussein Z
QJM; 2016 Apr; 109(4):289. PubMed ID: 26803152
[No Abstract] [Full Text] [Related]
13. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
[TBL] [Abstract][Full Text] [Related]
14. Denosumab for management of refractory hypercalcaemia in recurrent parathyroid carcinoma.
Nadarasa K; Theodoraki A; Kurzawinski TR; Carpenter R; Bull J; Chung TT; Drake WM
Eur J Endocrinol; 2014 Sep; 171(3):L7-8. PubMed ID: 24939719
[No Abstract] [Full Text] [Related]
15. [Refractory hypercalcemia in patient with lung cancer].
Grzywacz A; Dziuk M; Niemczyk S
Pol Merkur Lekarski; 2014 Apr; 36(214):261-4. PubMed ID: 24868900
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent.
Collins MT; Skarulis MC; Bilezikian JP; Silverberg SJ; Spiegel AM; Marx SJ
J Clin Endocrinol Metab; 1998 Apr; 83(4):1083-8. PubMed ID: 9543122
[TBL] [Abstract][Full Text] [Related]
17. First Japanese patient treated with parathyroid hormone peptide immunization for refractory hypercalcemia caused by metastatic parathyroid carcinoma.
Horie I; Ando T; Inokuchi N; Mihara Y; Miura S; Imaizumi M; Usa T; Kinoshita N; Sekine I; Kamihara S; Eguchi K
Endocr J; 2010; 57(4):287-92. PubMed ID: 20051648
[TBL] [Abstract][Full Text] [Related]
18. Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab.
Khoury N; Chang J; Gru AA; Whyte MP
J Clin Endocrinol Metab; 2012 Sep; 97(9):3051-5. PubMed ID: 22730513
[TBL] [Abstract][Full Text] [Related]
19. Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Tigas S; Tsatsoulis A
QJM; 2017 Jan; 110(1):53-54. PubMed ID: 28011856
[No Abstract] [Full Text] [Related]
20. Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma - Effective Therapy with Denosumab.
Harsch IA; Konturek PC
Am J Case Rep; 2019 Sep; 20():1325-1330. PubMed ID: 31492829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
